Piriprost (potassium salt) (Synonyms: U-60257B) |
| Catalog No.GC16046 |
5-lipoxygenase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 88851-62-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Piriprost (U 60257) is a leukotriene synthesis inhibitor [1].
Leukotrienes belong to a family of eicosanoid inflammatory mediators produced in leukocytes. Leukotrienes mainly act on a subfamily of G protein-coupled receptors. The production of leukotrienes is implicated in triggerring contractions in the smooth muscles lining the bronchioles and is a major cause of inflammation in asthma and allergic rhinitis [2].
Piriprost inhibited the formation of 5-hydroxyeicosatetraenoic acid (5-HETE), LTB4, and the sulfidopeptide leukotrienes with the IC50 values ranged from 9 to 14 μM for the mouse mast cells and 15-50 μM for the basophil leukemia cells. Piriprost weakly inhibited the solubilized LTC synthase of rat basophil leukemia cells with the IC50 of 1.5 mM [1]. Piriprost increased alkaline phosphatase (ALP) activity in cultured endometrial stromal cells. Piriprost (100 μM) inhibited 5-lipoxygenase activity and decreased 5-hydroxy-eicosatetraenoic acid (a 5-lipoxygenase product) by 53% [3].
In smoke-exposed rabbits, pretreatment with piriprost attenuated the smoke-induced increase in alveolar-capillary barrier permeability and decrease in plasminogen activator activity and causes a swelling of type I alveolar epithelium [4].
References:
[1] Bach M K, Brashler J R, White G J, et al. Experiments on the mode of action of piriprost (U-60,257), an inhibitor of leukotriene formation in cloned mouse mast cells and in rat basophil leukemia cells[J]. Biochemical pharmacology, 1987, 36(9): 1461-1466.
[2] Smith M J H, Ford‐Hutchinson A W, Bray M A. Leukotriene B: a potential mediator of inflammation[J]. Journal of Pharmacy and Pharmacology, 1980, 32(1): 517-518.
[3] Cejic S S, Kennedy T G. Examination of the effects of piriprost (U-60,257 B) on alkaline phosphatase activity of rat endometrial stromal cells in vitro[J]. Prostaglandins, 1991, 42(2): 179-189.
[4] itten M L, Grad R, Quan S F, et al. Piriprost pretreatment attenuates the smoke-induced increase in 99mTcDTPA lung clearance[J]. Experimental lung research, 1990, 16(4): 339-353.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *